> ## Content Index > Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt > Use this file to discover other available public pages before exploring further. # FDA Advisers Vote 17-0 to Recommend Opill for Over-the-Counter Birth Control - URL: https://www.theamericanquorum.com/taq-historical-2023-05-13-healthcare/ - Published: 2023-05-14T03:59:00.000Z - Updated: 2023-05-14T03:59:00.000Z - Description: FDA advisers voted 17-0 that the benefits of nonprescription Opill outweigh the risks, bringing the U.S. closer to its first over-the-counter daily oral contraceptive. - Author: Kenneth R. Deans Jr. - Tags: Healthcare, #Import 2026-09-01 00:55 A panel of Food and Drug Administration advisers voted unanimously Wednesday that the benefits of making the progestin-only contraceptive Opill available without a prescription outweigh the risks, moving the United States closer to its first over-the-counter daily oral birth-control pill. The **17-0 vote** followed two days of discussion about adherence, label comprehension, contraindications and whether consumers can safely select and use the medicine without direct clinician supervision. The FDA’s [meeting record](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-9-10-2023-joint-meeting-nonprescription-drugs-advisory-committee-and-obstetrics-reproductive-and?ref=theamericanquorum.com) identifies the application as supplemental NDA 017031/S-041 for Opill, a 0.075-mg norgestrel tablet submitted by Laboratoire HRA Pharma. Advisory-committee recommendations are nonbinding, so the agency still must make the final regulatory decision. ## A 50-year-old prescription medicine seeks a new route to patients Opill is a progestin-only pill, sometimes called a mini-pill, and does not contain estrogen. Norgestrel has been used as a prescription contraceptive in the United States since 1973\. HRA Pharma, now part of Perrigo, is asking FDA to allow consumers to buy it directly without obtaining a prescription. In a [statement after the vote](https://investor.perrigo.com/2023-05-10-FDA-Joint-Advisory-Committee-Votes-in-Favor-of-Perrigos-Opill-R-Daily-Oral-Contraceptive-for-OTC-Use?ref=theamericanquorum.com), Perrigo said its development program included label-comprehension studies, self-selection research and an actual-use trial designed to test whether consumers could identify when the product is appropriate and follow the once-daily instructions. The company argues that removing the prescription requirement could reduce access barriers for people who have difficulty obtaining appointments, transportation or prescription refills. The application arrives at a moment when reproductive-health policy is under intense national scrutiny. Since the Supreme Court overturned Roe v. Wade last year, state abortion laws have changed rapidly, increasing attention to contraception access. But the FDA’s decision is formally a drug-regulatory question: whether Opill can meet the standards for nonprescription use based on safety, effectiveness and consumers’ ability to use the label without professional supervision. ## The panel confronts imperfect adherence data FDA reviewers raised concerns before and during the meeting about the quality of some study data and whether users would take the pill consistently enough. Progestin-only contraceptives are sensitive to missed or delayed doses, so adherence is central to effectiveness. The agency also examined whether people with contraindications — particularly current or past breast cancer — would recognize warnings and avoid the product. [The Washington Post reported](https://www.washingtonpost.com/health/2023/05/10/birth-control-pill-over-the-counter-fda/?ref=theamericanquorum.com) that committee members acknowledged limitations in the data but ultimately concluded the evidence was adequate to support self-use. Panelists also noted that imperfect adherence already occurs with prescription oral contraceptives and questioned whether requiring a clinician visit materially solves that problem. Some FDA concerns focused on the actual-use study, including inconsistencies in reported pill-taking behavior. The applicant responded that additional analyses did not show a systematic flaw sufficient to invalidate the results. The advisers were left to judge not whether the evidence was perfect, but whether the expected public-health benefits outweighed the foreseeable risks in a nonprescription setting. ## Access weighs heavily in the benefit-risk calculation The panel repeatedly returned to access. Oral contraceptives are more effective than several contraceptive methods already available over the counter, including condoms and spermicides, when used correctly. Eliminating the prescription step could particularly affect adolescents, people without regular healthcare access, those in rural areas and individuals who face cost or scheduling barriers. A [PBS NewsHour report based on Associated Press reporting](https://www.pbs.org/newshour/politics/fda-panel-backs-first-ever-birth-control-pill-sold-without-prescription?ref=theamericanquorum.com) described the vote as a potential turning point after decades in which daily oral contraception has required a prescription in the United States. Advisers expressed confidence that people across age groups could use Opill appropriately if the labeling is clear enough, while also recognizing that no contraceptive method is completely free of misuse or failure. [NPR reported](https://www.lpm.org/news/2023-05-10/advisers-to-the-fda-back-first-over-the-counter-birth-control-pill?ref=theamericanquorum.com) that the panel’s recommendation was unanimous and that FDA is not obligated to follow it. The distinction matters because the committee is advisory: Wednesday’s vote strongly supports approval, but Opill remains prescription-only unless and until the agency changes the product’s status. ## Safety differs from estrogen-containing pills Most oral contraceptives used in the United States combine estrogen with a progestin. Opill contains only a progestin, which gives it a different risk profile. Estrogen-containing pills carry additional concerns for some patients, including elevated risk of blood clots in certain circumstances. Progestin-only pills generally have fewer of those restrictions, although they still are not appropriate for everyone. The [Reuters account published by The Guardian](https://www.theguardian.com/us-news/2023/may/10/birth-control-pill-over-counter-fda?ref=theamericanquorum.com) noted that advisers remained positive about the medicine’s effectiveness in the general population, adolescents and people with limited literacy despite FDA reviewers’ concerns about inappropriate use. The central contraindication discussed during the meeting was breast cancer, because progestins can be inappropriate for people with current or certain prior hormone-sensitive cancers. The label therefore carries unusual importance in an over-the-counter model. Consumers must understand both how frequently to take the pill and who should not use it. FDA’s nonprescription standard depends on ordinary consumers being able to make those decisions from labeling alone, without relying on a physician or pharmacist to screen them first. ## The vote could reshape contraceptive delivery If FDA ultimately approves the switch, Opill would become the first daily oral contraceptive sold without a prescription in the United States. That could shift contraception from an appointment-based model toward direct retail access, though price, insurance coverage and pharmacy stocking would still determine how accessible the product is in practice. [TIME reported](https://time.com/6278740/over-the-counter-birth-control-pill-fda/?ref=theamericanquorum.com) that committee members viewed the vote as a significant women’s-health milestone and emphasized the comparatively low medical risk of the progestin-only formulation. The panel’s deliberations also made clear that over-the-counter status does not eliminate the need for routine preventive care; it separates access to this contraceptive from the requirement to obtain a prescription first. The potential public-health effect will depend on who uses the product. If nonprescription access mainly shifts existing pill users away from prescriptions, the effect may be convenience. If it reaches people who otherwise would use less effective contraception or no contraception, the effect could include fewer unintended pregnancies. Perrigo’s application is built around that second possibility. ## FDA now makes the final decision The agency must weigh the committee’s unanimous recommendation against the same study limitations its reviewers highlighted. Historically, FDA often follows advisory committees but retains full authority to approve, reject or seek additional information. The company expects a decision later this year, but the panel vote does not guarantee the outcome. For now, the regulatory record supports a clear conclusion: 17 independent advisers believe the benefits of over-the-counter Opill outweigh its risks. The decision places the burden back on FDA to determine whether a prescription requirement still adds enough safety value to justify the access barrier it creates. If the agency agrees, the change would be more than a new retail option. It would mark the first time a daily hormonal contraceptive in the United States moves from clinician-mediated prescription access to direct consumer purchase — a shift that could influence future applications for other contraceptive products and reshape how reproductive healthcare is delivered.